Astrazeneca (AZN) Inventory (2009 - 2026)

Astrazeneca (AZN) has reported Inventory for 18 consecutive years, with $6.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory rose 11.66% year-over-year to $6.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 11.66% YoY), while the FY2025 annual figure was $6.6 billion, up 24.0% from the prior year.
• Inventory came in at $6.6 billion for Q1 2026 at Astrazeneca, roughly flat from $6.6 billion in the prior quarter.
• The five-year high for Inventory was $7.6 billion in Q1 2022, with the low at $4.7 billion in Q4 2022.
• Average Inventory over 5 years is $5.8 billion, with a median of $5.7 billion recorded in 2024.
• The largest YoY upside for Inventory was 125.56% in 2022 against a maximum downside of 51.77% in 2022.
• Year by year, Inventory stood at $4.7 billion in 2022, then gained by 15.43% to $5.4 billion in 2023, then decreased by 2.51% to $5.3 billion in 2024, then advanced by 24.0% to $6.6 billion in 2025, then increased by 0.2% to $6.6 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $6.6 billion, $6.6 billion, and $6.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.